Meet the VISION aeries

Inspiration, imagination, and innovation. We share this passion for finding new approaches to protecting vision. United by great science, deep clinical insight, and a singular focus on your ophthalmic needs, we see the possibilities ahead and invite you to join us in creating the future of eye care.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye.

See the future of eye care with Aerie.
www.aeriepharma.com

Follow the meeting on Twitter: #Glaucoma360
It is our sincere pleasure to welcome you to the 7th Annual Glaucoma 360: New Horizons Forum, hosted by Glaucoma Research Foundation.

This important meeting provides a unique opportunity to bring together leaders in medicine, science, industry, venture capital, and the FDA to discuss emerging ideas in glaucoma and encourage collaboration to accelerate their development for clinical use.

Since its establishment in 2012, this annual forum continues to grow and provide the ultimate opportunity to highlight important advances and facilitate networking between these essential groups. As a result, there are now more effective therapies and diagnostic tools in clinical practice today to help doctors manage the disease more effectively.

But, unmet medical needs remain in glaucoma. Glaucoma Research Foundation is resolute in its mission to preserve vision and continue its role as a catalyst in the advancement of research towards new treatments and a cure.

Glaucoma 360 would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board, Program and Steering Committees who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel. Over the past seven years, the field has grown substantially and we are honored and grateful to all of you, for your ongoing dedication to helping patients. Because of your commitment, we now have more options to care for patients than ever before.

All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Thank you for your wonderful partnership in our mission. Together, we can truly make a difference in the lives of people living with glaucoma.

Adrienne L. Graves, PhD
Co-Founder and Co-Chair, Glaucoma 360
Director, Glaucoma Research Foundation

Andrew G. Iwach, MD
Co-Founder and Co-Chair, Glaucoma 360
Board Chair, Glaucoma Research Foundation

Wi-Fi sponsored by Santen Inc., Network: Palace Meetings, Password: 2018G360
### PROGRAM

**REGISTRATION, BREAKFAST AND EXHIBITS**

**8:00 – 8:06 am**

**WELCOME AND OPENING REMARKS**
Adrienne L. Graves, PhD and Andrew G. Iwach, MD
Co-Founders and Co-Chair, Glaucoma 360

**8:06 – 8:32 am**

**OPENING KEYNOTE ADDRESS — Drs. Henry and Frederick Sutro Memorial Lecture**
Iqbal Ike K. Ahmed, MD, FRCS
Medical Director, Prion Eye Institute; Associate Professor of Ophthalmology, University of Toronto; Clinical Professor of Ophthalmology, University of Utah

**MORNING CATALYST**
Joel S. Schuman, MD, FACS
Professor of Neuroophthalmology and Ophthalmology, Stanford University; Member, Catalyst for a Cure Biomarker Initiative

**8:34 – 9:09 am**

**NEW HORIZONS IN VIRTUAL REALITY**
Andrew D. Huberman, PhD
Associate Professor of Neuroophthalmology and Ophthalmology, Stanford University; Member, Catalyst for a Cure Biomarker Initiative

**9:09 – 9:14 am**

**INDUSTRY SPOTLIGHT — Santen Inc.**
Ram Palanki, PharmD
Senior Vice President of Commercial, Americas

**9:14 – 10:21 am**

**NEW HORIZONS IN GLAUCOMA DEVICES**
E. Randy Craven, MD
Chief, Wilmer Eye Institute – Bethesda; Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine

**10:11:26 – 11:31 am**

**INDUSTRY SPOTLIGHT — Allergan, Inc.**
Ram Palanki, PharmD, Senior Vice President of Commercial, Americas

**10:12:09 – 12:14 pm**

**INDUSTRY SPOTLIGHT — Aerie Pharmaceuticals, Inc.**
Brooke C. Stromberger, PhD
Managing Director and Head of West Coast Biotechnology Banking, Piper Jaffray

**11:26 – 11:31 am**

**INDUSTRY SPOTLIGHT — Santen Inc.**
Ram Palanki, PharmD
Senior Vice President of Commercial, Americas

**11:31 – 12:09 pm**

**FUNDING INNOVATIONS: VENTURE CAPITAL PANEL DISCUSSION**
Emmett Cunningham, Jr., MD, PhD, MPH
Partner, Ceres Ventures

**12:09 – 12:14 pm**

**INDUSTRY SPOTLIGHT — Aerie Pharmaceuticals, Inc.**
Brooke C. Stromberger, PhD
Managing Director and Head of West Coast Biotechnology Banking, Piper Jaffray

**12:14 – 1:10 pm**

**NETWORKING BUFFET LUNCHEON**

**1:12 – 2:30 pm**

**NEW HORIZONS IN GLAUCOMA DRUG DELIVERY**
James D. Brandt, MD
Director of Glaucoma Service, Professor of Ophthalmology and Visual Science, UC Davis

**Panelists**
- Allergan, Inc., Jag Dosanjh, Senior Vice President, Eye Care
- Glaukos Corporation, Chris M. Calcaterra, Chief Operating Officer
- Heidelberg Engineering, Kfir Azoulay, MBA, Head of Strategy
- Johnson & Johnson Vision, Jane Rady, Vice President, Business Development, Surgical
- New World Medical, Rafael Chan, Chief Commercial Officer
- Santen Inc., Ram Palanki, PharmD, Senior Vice President of Commercial
- Carl Zeiss Meditec, Inc., Angelo Rago, Global Head, Ophthalmic Diagnostics

---

Follow the meeting on Twitter: #Glaucoma360
PROGRAM (continued)

2:30 – 2:35 pm
Speaker
James C. Tsai, MD, MBA, FACS
Co-Director, Division of International Ophthalmology, John A. Moran Eye Center, Global Outreach Division, University of Utah

2:35 – 2:40 pm
Moderators
Cynthia Mattox, MD, FACS
Co-Founder, Sacramento Eye Consultants

2:40 – 2:50 pm
Panelists
Richard A. Lewis, MD
Atlanta Ophthalmology Associates

2:50 – 3:00 pm
Panelists
Karen Y. Torrejon, PhD, Founder and Chief Science Officer, Glauconix Therapeutics

2:50 – 2:55 pm
Panelists
Ram Palanki, PharmD, Senior Vice President of Commercial, Americas, Bausch + Lomb

2:55 – 3:00 pm
Panelists
Cheryl Rowe-Rendleman, PhD, Managing Consultant, Omar Consulting

3:00 – 3:15 pm
Panelists
Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology, Novartis Alcon Pharmaceuticals

3:15 – 3:30 pm
Panelists
Malvina Eydelman, MD, Deputy Director, Division of Transplant & Ophthalmology Products, Center for Drug Evaluation & Research, FDA

3:30 – 3:45 pm
Panelists
Karen Y. Torrejon, PhD, Founder and Chief Science Officer, Glauconix Therapeutics

3:45 – 4:00 pm
Panelists
Ram Palanki, PharmD, Senior Vice President of Commercial, Americas, Bausch + Lomb

4:00 – 4:15 pm
Panelists
Cheryl Rowe-Rendleman, PhD, Managing Consultant, Omar Consulting

4:15 – 4:30 pm
Panelists
Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology, Novartis Alcon Pharmaceuticals

4:30 – 5:00 pm
Panelists
Karen Y. Torrejon, PhD, Founder and Chief Science Officer, Glauconix Therapeutics

5:00 – 5:15 pm
Panelists
Ram Palanki, PharmD, Senior Vice President of Commercial, Americas, Bausch + Lomb

5:15 – 5:30 pm
Panelists
Cheryl Rowe-Rendleman, PhD, Managing Consultant, Omar Consulting

5:30 – 6:00 pm
Panelists
Melissa Liew, MD, Vice President and US Medical Head of Ophthalmology, Novartis Alcon Pharmaceuticals

6:00 – 7:00 pm
Panelists
Karen Y. Torrejon, PhD, Founder and Chief Science Officer, Glauconix Therapeutics

LEADERSHIP

THOMAS M. BRUNNER
President and Chief Executive Officer, Steering Committee, Glaucoma 360
Glaucoma Research Foundation
Mr. Brunner joined the Glaucoma Research Foundation after a 30-year career in the ophthalmic laser business. He helped introduce major advances including laser photocoagulation for diabetic retinopathy and laser treatment for secondary cataracts and glaucoma. He served 25 years on the Board of Directors for the American Society for Laser Medicine and Surgery who granted him a “Lifetime Achievement” Award. As an advisor or board member for startup companies, he supports new product development to treat glaucoma and other eye diseases. Tom graduated from Lehigh University with a degree in electrical engineering and a MBA from the University of Delaware.

L. JAY KATZ, MD
Director, Glaucoma Service, Wills Eye Hospital
Professor of Ophthalmology, Jefferson Medical College
Steering Committee, Glaucoma 360
Glaucoma Research Foundation
In 2017 Dr. Katz was appointed the Chief Medical Officer of KLAUS Corporation. He is on the advisory boards of Bausch + Lomb, Allergan, Aerie, and Merck. Dr. Katz is a former member of the board and past treasurer of the American Glaucoma Society and a diplomat and associate examiner for the American Board of Ophthalmology. His interests in glaucoma include drug evaluation, laser and medical management, optic nerve scanning methodologies, and glaucoma surgical techniques. After attending Yale University School of Medicine, he completed his ophthalmology residency at Yale and received glaucoma training at Wills Eye Hospital.

RUTH D. WILLIAMS, MD
President, Wheaton Eye Clinic
Steering Committee, Glaucoma 360
Glaucoma Research Foundation
Dr. Williams is the President of the Wheaton Eye Clinic, a 74-year-old ophthalmology practice providing eye care to more than 140,000 patients annually. She is a past president of the American Academy of Ophthalmology and represented ophthalmology at the AMA for a decade and chaired its specialty section. Dr. Williams received a Senior Achievement Award from the Academy and was chosen by her peers for the prestigious “Top Doctors” Award in Chicago. After attending Rush Medical College, she completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

ADRIENNE L. GRAVES, PHD
Independent Director, Akorn, Inc., Nicox S.A., Surface Pharmaceuticals, and TearLab Corporation
Co-Founder and Co-Chair, Glaucoma 360
Board of Directors,
Glaucoma Research Foundation
Adrienne L. Graves, PhD is a visual scientist by training and a global industry leader in ophthalmology. From 2002 to 2010 Dr. Graves was President and Chief Executive Officer of the US arm of Santen Inc., Japan’s largest ophthalmic pharmaceutical company. Dr. Graves held various Research and Development roles with Akorn Laboratories including Director of International Ophthalmology. In 2015, the Glaucoma Research Foundation gave her the Catalyst Award for her dedication and leadership in advancing ophthalmic innovation. Dr. Graves received her PhD from the University of Michigan and did a postdoctoral fellowship in visual neuroscience at the University of Paris.

ANDREW G. IWACH, MD
Executive Director, Glaucoma Center of San Francisco
Executive Director, Glaucoma Research and Education Group
Co-Founder and Co-Chair, Glaucoma 360
Chair, Board of Directors,
Glaucoma Research Foundation
Since 2000 Dr. Iwach has served on the Board of Directors for the Glaucoma Research Foundation. He is a Co-founder of the Eye Surgery Center of San Francisco and is an Associate Clinical Professor of Ophthalmology at UCSF and on the clinical faculty at California Pacific Medical Center. Dr. Iwach’s clinical research focuses on mitomycin-C use in filtering surgery, application of optical coherence tomography in glaucoma, selective laser trabeculoplasty, and numerous drug trials. He currently serves as a scientific reviewer for many top professional publications. Recently he received the Academy’s Life Achievement Award and the Academy’s Secretariat Award.
### ADVISORY BOARD

<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Position</th>
<th>Organization/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUART B. ABELSON, MBA</td>
<td>President, Chief Executive Officer</td>
<td>Ora, Inc.</td>
</tr>
<tr>
<td>ANTHONY P. ADAMIS, MD</td>
<td>Vice President, Global Head of Ophthalmology</td>
<td>Genentech, Inc.</td>
</tr>
<tr>
<td>JAMES D. BRANDT, MD</td>
<td>Director of Glaucoma Service</td>
<td>University of California, Davis</td>
</tr>
<tr>
<td>ERNEST CAVIN, PHD</td>
<td>President</td>
<td>Haag-Streit USA</td>
</tr>
<tr>
<td>PAUL CHANEY</td>
<td>President and Chief Executive Officer</td>
<td>PanOptica, Inc.</td>
</tr>
<tr>
<td>GEORGE A. CIOFFI, MD</td>
<td>Jean and Richard Deems Professor of Ophthalmology</td>
<td>Columbia University College of Physicians and Surgeons</td>
</tr>
<tr>
<td>ALAN S. CRANDALL, MD</td>
<td>Presidential Professor of Ophthalmology and Visual Services</td>
<td>John A. Moran Eye Center</td>
</tr>
<tr>
<td>EMMETT CUNNINGHAM, JR., MD, MD</td>
<td>Managing Partner</td>
<td>Canus Ventures</td>
</tr>
<tr>
<td>EUGENE DE JUAN, JR., MD</td>
<td>Founder and Vice-Chair</td>
<td>ForSight Labs</td>
</tr>
<tr>
<td>JOHN G. FLANAGAN, PHD, FCOPOTM</td>
<td>Dean, School of Optometry and Professor of Optometry and Vision Science</td>
<td>University of California, Berkeley</td>
</tr>
<tr>
<td>DAVID GUYER, MD</td>
<td>Partner</td>
<td>SV Life Sciences Advisers, LLC</td>
</tr>
<tr>
<td>EVE HIGGINBOTHAM, SM, MD</td>
<td>Vice Dean, Inclusion and Diversity Director</td>
<td>Perelman School of Medicine, University of Pennsylvania</td>
</tr>
<tr>
<td>H. DUNBAR HOSKINS, JR., MD</td>
<td>Co-Founder and Emeritus Director</td>
<td>Glaucoma Research Foundation</td>
</tr>
<tr>
<td>WENDE HUTTON</td>
<td>General Partner</td>
<td>Canaan Partners</td>
</tr>
<tr>
<td>ELIOT LAZAR, MD</td>
<td>President</td>
<td>eICON Medical</td>
</tr>
<tr>
<td>PAUL P. LEE, MD, JD</td>
<td>F. Bruce Fulk Professor and Chair, Department of Ophthalmology and Visual Sciences</td>
<td>Kellogg Eye Center, University of Michigan</td>
</tr>
<tr>
<td>RICHARD L. LINDBERG, MD</td>
<td>Founder</td>
<td>Minnesota Eye Consultants, PA</td>
</tr>
<tr>
<td>WILLIAM J. LINK, PHD</td>
<td>Founder</td>
<td>Flying Life Partners</td>
</tr>
<tr>
<td>CYNTIA MATTOX, MD, FACS</td>
<td>Director of the Glaucoma and Cataract Service</td>
<td>New England Eye Center</td>
</tr>
<tr>
<td>JAMES MAZZO</td>
<td>Global President, Ophthalmic Devices</td>
<td>Carl Zeiss Meditec, Inc.</td>
</tr>
<tr>
<td>J. CASEY McGLYNN, JD</td>
<td>Partner</td>
<td>Wilson Sonsini Goodrich &amp; Rosati</td>
</tr>
<tr>
<td>GARY D. NOVACK, PHD</td>
<td>President</td>
<td>Pharmacologic Development, Inc.</td>
</tr>
<tr>
<td>DAVID E.J. PYOTT, CBE</td>
<td>President</td>
<td>Allergan, Inc.</td>
</tr>
<tr>
<td>THOMAS W. SAMUELSON, MD</td>
<td>Founding Partner, Minnesota Eye Consultants</td>
<td>Adjunct Associate Professor of Ophthalmology, University of Minnesota</td>
</tr>
</tbody>
</table>

**Dr. Stuart Abelson, MBA**
President, Chief Executive Officer
Ora, Inc.

**Dr. Anthony Adamis, MD**
Vice President, Global Head of Ophthalmology
Genentech, Inc.

**Dr. James Brandt, MD**
Director of Glaucoma Service
Professor of Ophthalmology and Vision Science
University of California, Davis

**Mr. Ernest Cavin, PhD**
President
Haag-Streit USA

**Mr. Paul Chaney**
President and Chief Executive Officer
ParOptica, Inc.

**Dr. George Cioffi, MD**
Jean and Richard Deems Professor of Ophthalmology
Edward S. Harkness Professor and Chairman
Columbia University College of Physicians and Surgeons

**Dr. Alan Crandall, MD**
Presidential Professor of Ophthalmology and Visual Services
Senior Vice Chair, Director of Glaucoma and Cataract
Co-Director, Division of International Ophthalmology
John A. Moran Eye Center

**Dr. Emmett Cunningham, Jr., MD, PhD, MPH**
Managing Partner
Canus Ventures

**Dr. Eugene De Juan, Jr., MD**
Founder and Vice-Chair
ForSight Labs

**Dr. John Flanagan, PhD, FCOPOTM**
Dean, School of Optometry and Professor of Optometry and Vision Science
University of California, Berkeley

**Mr. David Guyer, MD**
Partner
SV Life Sciences Advisers, LLC

**Eve Higginbotham, SM, MD**
Vice Dean, Inclusion and Diversity
Perelman School of Medicine
University of Pennsylvania

**Dr. H. Dunbar Hoskins, Jr., MD**
Co-Founder and Emeritus Director
Glaucoma Research Foundation
Former Executive Vice President
American Academy of Ophthalmology

**Ms. Wende Hutton**
General Partner
Canaan Partners

**Dr. Eliot Lazar, MD**
President
eICON Medical

**Dr. Paul P. Lee, MD, JD**
F. Bruce Fulk Professor and Chair,
Department of Ophthalmology and Visual Sciences
Directors, W.K. Kellogg Eye Center
University of Michigan

**Dr. Richard Lindstrom, MD**
Founder
Minnesota Eye Consultants, PA

**Dr. William J. Link, PhD**
Founder, Flying Life Partners
Managing Director, Versant Ventures

**Dr. Cynthia Mattox, MD, FACS**
Director of the Glaucoma and Cataract Service,
New England Eye Center
Associate Professor and Vice-Chair,
Department of Ophthalmology
Tufts University School of Medicine

**Mr. J. Casey McGlynn, JD**
Partner
Wilson Sonsini Goodrich & Rosati

**Mr. Gary Novack, PhD**
President
Pharmacologic Development, Inc.

**Mr. David E.J. Pyott, CBE**
Former Chairman of the Board,
President and Chief Executive Officer (1998-2015)
Allergan, Inc.

**Dr. Thomas W. Samuelson, MD**
Founding Partner, Minnesota Eye Consultants
Adjunct Associate Professor of Ophthalmology,
University of Minnesota

**Dr. Kuldev Singh, MD, MPH**
Professor of Ophthalmology
Director, Glaucoma Service
Stanford University School of Medicine

**Dr. George Spaeth, MD**
Louis Esposito Research Professor of Ophthalmology
Director Emeritus, Glaucoma Service
Wills Eye Hospital/Jefferson Medical College

**Ms. Ellen Strahs, MD, MHSC**
Director of the Glaucoma and Cataract Service,
New England Eye Center
Associate Professor and Vice-Chair,
Department of Ophthalmology
Tufts University School of Medicine

**Mr. Tracy M. Valorie, MBA**
Senior Vice President and General Manager,
US Pharmaceutical and Surgical
Bausch + Lomb

**Mr. Robert N. Weinreb, MD**
Chairman & Director, Shiley Eye Center
Director, Hamilton Glaucoma Center
University of California, San Diego

**Ms. Ruth D. Williams, MD**
President
Wheaton Eye Clinic

**Dr. M. Roy Wilson, MD, MS**
President
Wayne State University
**FOR THE REDUCTION OF IOP IN MODERATE TO SEVERE OPEN-ANGLE GLAUCOMA AT THE TIME OF CATARACT SURGERY**

ONE CYPASS® MICRO-STENT IS ALL IT TAKES TO CONNECT TO SAFE, CONSISTENT, LONG-TERM IOP CONTROL

IN THE COMPASS STUDY AT TWO YEARS2:

- 72.5% of patients achieved a 20% reduction in IOP (n=374)
- 93% of patients were medication free
- Safety profile similar to cataract surgery alone

FOR AN EXPERIENCE LIKE NO OTHER, CONNECT WITH AN ALCON REPRESENTATIVE TODAY.

**IMPORTANT PRODUCT INFORMATION**

**CAUTION:** FEDERAL USA LAW RESTRICTS THIS DEVICE TO SALE BY OR ON THE ORDER OF A PHYSICIAN. INDICATION: The Micro-Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG). CONTRAINDICATIONS: Use of the CyPass Micro-Stent is contraindicated in the following circumstances or conditions: (1) in eyes with angle-closure glaucoma, and (2) in eyes with traumatic, instigating, uncontrolled, or neovascular glaucoma or disc-based conjunctival neovascularization of the anterior chamber angle. MRI INFORMATION: The CyPass Micro-Stent is magnetic resonance (MR) Safe. The implant is constructed of non-particle-conducting, non-metallic, non-magnetic polymer that poses no hazards in all magnetic resonance imaging environments. WARNINGS: Surgery should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. PRECAUTIONS: Gonioscopy should be performed prior to surgery to exclude primary open-angle glaucoma with medications, in patients 21 years of age or younger, in eyes with significant prior trauma, chronic inflammation, eyes with an abnormally anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with neovascular glaucoma, eyes with pseudohypoparathyroidism or pigmentary glaucoma, eyes with other secondary open-angle glaucoma, eyes that have undergone prior intraocular glaucoma surgery or cilioablatve procedures, eyes with laser trabeculoplasty performed ≤ 3 months prior to the surgical screening visit, eyes with unmedicated IOP less than 11 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iridociliary injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation for visually significant cataract. The safety and effectiveness of use of more than a single Micro-Stent is not known. ADVERSE EVENTS: In a randomized, multicenter clinical trial comparing cataract surgery with the CyPass Micro-Stent to cataract surgery alone, the most common postoperative adverse events included BCVA loss of 10 or more letters at 3 months after surgery (8.8% for the CyPass Micro-Stent vs. 13.5% for cataract surgery only), anatomic chamber cell and flare requiring retreatment 10 or more days after surgery (5.6% vs. 3.8%), worsening of visual field mean deviation by ≥ 2.5 or more decibels (6.7% vs. 5.9%), IOP increase of 10 or more mmHg 2 or more days after surgery (4.1% vs. 2.5%) and corneal edema 30 or more days after surgery, or severe in nature (5.9% vs. 3.1%). ATTENTION: PLEASE REFER TO THE INSTRUCTIONS FOR A COMPLETE LIST OF CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, AND ADVERSE EVENTS.

© 2017 Novartis 09/17 US-CYP-17-E-2272

---


---

**REFERENCES:**


---

**PROGRAM COMMITTEE**
BEN BACKUS, PHD
Vivid Vision
Chief Science Officer

Ben Backus was a professor at SUNY Optometry in New York until his recent move to be CSO at Vivid Vision in San Francisco. Dr. Backus is now applying his knowledge of psychophysics to develop a new mobile light-weight perimeter for people with glaucoma to do visual field testing at home. He trained in mathematics (BA Swarthmore), human vision (PhD UC Berkeley), and visual neuroscience (postdoc Stanford). The NIH, NSF, and HFSP fund his research.

KFIR AZOULAY, MBA
Corporate Head of Strategy
Klear Vision

Mr. Azoulay oversees business development as well as the company’s other strategic initiatives. Prior to Klear Vision, he was a partner at Bain & Company where he worked with various industries and firms on strategy, growth, and digital transformation. He holds an MBA from the Massachusetts Institute of Technology (MIT) and has worked in various roles at a number of companies, including leading the digital transformation at Ford Motor Company and managing strategy and operations at GE Healthcare.

SPEAKERS, MODERATORS, PARTICIPANTS

LAMA AL-ASWAD, MD, MPH
Associate Professor of Ophthalmology
Columbia University Medical Center

Dr. Al-Aswad is Associate Professor of Ophthalmology at CUMC and the glaucoma fellowship director. She received her MD from Damascus University, and completed a research fellowship at the MEEL Harald Medical School. She completed her residency at SUNY Downstate and Fellowship at UT Memphis. She received her MPH from Columbia University, Mailman School of Public Health with an emphasis on healthcare policy and management. She has been the director of the glaucoma screening program since 2006 and in 2016 she launched Tele-ophthalmology for the four leading causes of blindness.

JULIET BAKKER
Managing Director and Founder
Longitude Capital

Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a BSc from the College of Agriculture and Life Sciences at Cornell University (“CALS”).


DRS. HENRY AND FREDERICK SUTRO MEMORIAL LECTURER
IQBAL IKE F. AHMED, MD, FRCSC
Medical Director, Prism Eye Institute
Associate Professor of Ophthalmology, University of Toronto

Dr. Ahmed’s areas of subspecialty expertise include: surgical management of glaucoma, the complex cataract, and management of cataract and intraocular lens complications. He is actively involved in research and medical education at a national and international level and has received many research grants and has designed diamond scalpels for glaucoma surgery, microsurgical instrumentation, and devices, implants, and techniques for the management of the dislocated cataract and glaucoma. He has published numerous peer-reviewed articles and book chapters and has won many awards and honors for papers, posters, and videos and has given more than 500 scientific presentations and lectures around the world.

Opening Keynote Address

DR. JULIET BAKKER
Managing Director and Founder
Longitude Capital

Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. Ms. Bakker holds an M.P.A. from the John F. Kennedy School of Government at Harvard University and a BSc from the College of Agriculture and Life Sciences at Cornell University (“CALS”).
INTRODUCING VYZULTA

Now available in pharmacies nationwide.

For more information, visit vyzultanow.com
**INDICATIONS AND USAGE**

SIMBRINZA® (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

**Dosage and Administration**

The recommended dose is one drop of SIMBRINZA® Suspension in the affected eye(s) three times daily. Shake well before use. SIMBRINZA® Suspension may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

**IMPORTANT SAFETY INFORMATION**

**Contraindications**

SIMBRINZA® Suspension is contraindicated in patients who are hypersensitive to any component of this product and neonates and infants under the age of 2 years.

**Warnings and Precautions**

Sulfonamide Hypersensitivity Reaction—Brinzolamide is a sulfonamide, and although administered topically, it is absorbed systematically. Sulfonamide attributable adverse reactions may occur. Fatalities have occurred due to severe reactions to sulfonamides. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or hypersensitivity occur, discontinue the use of this preparation.

**SIDE EFFECTS**

The most common adverse reactions included blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, fatigue/drowsiness, conjunctival follicles, ocular allergic reactions, ocular pain, elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

**REFERENCES**

Dr. Cleland's research includes the etiology, diagnosis, treatment, and societal impact of glaucoma, cataracts, and age-related macular degeneration, including quality-of-life research for patients impacted by these eye diseases. Dr. Cleland studied chemistry at Duke University, received his MD degree with Alpha Omega Alpha honors from the Medical College of Virginia, completed an ophthalmology residency at University of Illinois-Chicago followed by a glaucoma fellowship at Johns Hopkins University, and earned a PhD in epidemiology from UCLA in 1997.

**SPEAKERS, MODERATORS, PARTICIPANTS**

- **Jeffrey L. Cleland, PhD**
  President and Chief Executive Officer
  Greybug Vision, Inc.
  Dr. Cleland has 25 years of industry experience in research and development. He has played major roles in obtaining more than $400 million in capital, including over $100 million in capital raised as CEO of Versars (VYAR), where he led one of the top biotech IPOs of all time. He has directly managed all aspects of pharmaceutical development and late-stage research. Dr. Cleland has authored more than 100 articles and 4 books, and holds several issued patents. He holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology.

- **Anne L. Coleman, MD, PhD**
  Vice Chair of Department of Ophthalmology
  Stein Eye Institute
  Frances and Ray Stark Foundation Professor of Ophthalmology
  Stein Eye Institute of the David Geffen School of Medicine, University of California, Los Angeles
  Professor of Epidemiology
  Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles
  Dr. Coleman’s research includes the etiology, diagnosis, treatment, and societal impact of glaucoma, cataracts, and age-related macular degeneration, including quality-of-life research for patients impacted by these eye diseases. Dr. Coleman studied chemistry at Duke University, received his MD degree with Alpha Omega Alpha honors from the Medical College of Virginia, completed an ophthalmology residency at University of Illinois-Chicago followed by a glaucoma fellowship at Johns Hopkins University, and earned a PhD in epidemiology from UCLA in 1997.

- **Alan S. Crandall, MD**
  Presidential Professor of Ophthalmology
  and Visual Services; Senior Vice Chair, Director of Glaucoma and Cataract; Co-Director, Division of International Ophthalmology
  John A. Moran Eye Center Global Outreach Division, University of Utah
  Dr. Crandall is a member of the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgeons, American Glaucoma Society, the European Society of Cataract and Refractive Surgeons, as well as the International Intraocular Implant Club. He received his medical degree from the University of Utah School of Medicine. Dr. Crandall completed his internship in surgery at the University of Pennsylvania Medical Center as well as his residency and fellowship in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He joined the University of Utah Ophthalmology Department in 1981.

- **E. Randy Craven, MD, FACS**
  Associate Professor
  Wilmer Eye Institute and Johns Hopkins University Medical Director
  Wilmer Eye Institute – Bethesda
  Dr. Craven is an associate professor at the Wilmer Eye Institute. He is an associate professor at Johns Hopkins University. In the 1990s until 2013, he was the president of Glaucoma Consultants of Colorado in the Denver area and participated in over 100 clinical trials. He served as the chief of Glaucoma at the King Khaled Eye Specialist Hospital in Riyadh Saudi Arabia from 2013 to 2017. His current role is the Medical Director of the Bethesda location for Wilmer Eye Institute.

- **Emmett Cunningham, Jr., MD, PhD, MPH**
  Managing Partner
  Clarus Ventures
  Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease. He joined Clarus Ventures in 2006. He is Director of the Uveitis Service at California Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford University, and a Research Associate at the Francis I. Proctor Foundation, UCSF School of Medicine. Dr. Cunningham received his MD and MPH from Johns Hopkins University, his PhD from UC San Diego, and completed his residency and fellowship at UCSF. He completed additional fellowships at Moorfields Eye Hospital in London and the Wilmer Eye Institute.

- **Eugene De Juan, Jr., MD**
  Founder and Vice-Chairman
  ForSight Labs
  Dr. De Juan serves as Vice-Chairman of ForSight Labs and is the Jean Kelly Stock Distinguished Professor in Ophthalmology at UCSF. He has participated in the development of a number of new technologies and venture-funded companies. He has previously served as Professor of Ophthalmology at USC and CEO at the Barony Retina Institute, Co-Director of Vitreoretinal Service at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, Director of the Microsurgery Advanced Design Laboratory, and Joseph E. Green Professor of Ophthalmology. He completed his MD and internship training at the University of South Alabama College of Medicine.
MORGAN V. FEDORCHAK, PHD
President and Chief Technology Officer, Otero Therapeutics, Assistant Professor of Ophthalmology, Bioengineering, and Clinical and Translational Science, University of Pittsburgh

Dr. Fedorchak is the Director of the Ophthalmic Biomaterials Laboratory at the University of Pittsburgh and a co-inventor of the SoliDrop technology, the basis for Otero’s controlled release glaucoma eye drop technology. She received her BS in Chemical Engineering from Carnegie Mellon University and her PhD in Bioengineering from the University of Pittsburgh.

TEJAL DESAI, PHD
Ernest L. Prien Endowed Professor and Chair, Dept. of Bioengineering and Therapeutic Sciences, School of Pharmacy and Medicine, University of California, San Francisco

Dr. Desai chairs the Institutional Review Board for human subject research at the New Jersey Medical School in Newark. He is also the Executive Vice President of the World Glaucoma Association. Dr. Fechtner is a highly regarded glaucoma educator. He has organized major glaucoma symposia for the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, the World Glaucoma Congress and the American Glaucoma Society. He has served on the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Review of Ophthalmology, and Video Journal of Ophthalmology.

SPEAKERS, MODERATORS, PARTICIPANTS

MALVINA EYDELMAN, MD
Division Director, Division of Ophthalmic Device Evaluation, FDA

Dr. Eydelman is a board-certified ophthalmologist. She received her undergraduate degree in Electrical Engineering from Cooper Union for the Advancement of Science and Art. She received her MD degree from Harvard Medical School and a PhD in Health Sciences and Technology from Massachusetts Institute of Technology. In 1995, Dr. Eydelman joined the FDA and has played a key role in assuring the safety and effectiveness of ophthalmic medical devices. She has been involved in standardization of ophthalmic devices as the US Expert Delegate to the International Standards Organization and FDA’s Liaison to the American National Standards Institute’s Committee for Ophthalmic Devices.

ROBERT D. FECHTNER, MD
Professor, Institute of Ophthalmology and Visual Science Director, Glaucoma Division, Rutgers New Jersey Medical School

Dr. Fechtner chairs the Institutional Review Board for human subject research at the New Jersey Medical School in Newark. He is also the Executive Vice President of the World Glaucoma Association. Dr. Fechtner is a highly regarded glaucoma educator. He has organized major glaucoma symposia for the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, the World Glaucoma Congress and the American Glaucoma Society. He has served on the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Review of Ophthalmology, and Video Journal of Ophthalmology.

JAG DOSANJH
Senior Vice President, Eye Care, Allergan, Inc.

Jag is responsible for the commercialization of the entire Eye Care portfolio in the US and co-chairs the R&D Governance Board for the pipeline development. Prior to this, he led the Retina, Dermatology, and SkinMedica business units, and the Managed Markets and Government Affairs. Jag also led the Global Strategic Marketing developing strategy and delivery of the pipeline within the pharmaceutical, device and aesthetics portfolios. Prior to joining Allergan, Jag worked at GlaxoSmithKline in several executive roles in both Europe and the US. He holds a BA in Business Studies from Sheffield in the UK.

ANDREW GITKIN
Managing Director and Head of West Coast Biotechnology Investment Banking, Piper Jaffray

Andrew has over 25 years of healthcare investment experience, most recently at Moelis & Company, where he was a Senior VP in the life sciences investment banking group. Andrew was previously with Saddle Point Asset Management where he was a managing member and healthcare portfolio manager. Prior to that, he was a VP at Tavistock Life Sciences and was CEO of Zephyr Sciences. Andrew was also a senior healthcare analyst in equity research at UBS and SalomonSmithBarney where he was awarded rankings by Institutional Investor and Greenwich Associates.

JAG DOSANJH
Senior Vice President, Eye Care, Allergan, Inc.

Jag is responsible for the commercialization of the entire Eye Care portfolio in the US and co-chairs the R&D Governance Board for the pipeline development. Prior to this, he led the Retina, Dermatology, and SkinMedica business units, and the Managed Markets and Government Affairs. Jag also led the Global Strategic Marketing developing strategy and delivery of the pipeline within the pharmaceutical, device and aesthetics portfolios. Prior to joining Allergan, Jag worked at GlaxoSmithKline in several executive roles in both Europe and the US. He holds a BA in Business Studies from Sheffield in the UK.

ANDREW GITKIN
Managing Director and Head of West Coast Biotechnology Investment Banking, Piper Jaffray

Andrew has over 25 years of healthcare investment experience, most recently at Moelis & Company, where he was a Senior VP in the life sciences investment banking group. Andrew was previously with Saddle Point Asset Management where he was a managing member and healthcare portfolio manager. Prior to that, he was a VP at Tavistock Life Sciences and was CEO of Zephyr Sciences. Andrew was also a senior healthcare analyst in equity research at UBS and SalomonSmithBarney where he was awarded rankings by Institutional Investor and Greenwich Associates.
ARVO Cogan Award for Contributions to Vision Science and Ophthalmology. Dr. Ophthalmology at UC San Diego. In 2016, joined the faculty at Stanford Biomarker Initiative. Huberman is member of the Glaucoma Research Foundation Catalyst for a Cure University. Dr. Huberman is a McKnight Foundation Neuroscience Scholar, a 18 Glaucoma Research Foundation Service and Assistant Professor of Ophthalmology at the New England Eye Center and Tufts University School of Medicine. Dr. Huberman holds an MD and an MBA from Northwestern University.

ANDREW D. HUBERMAN, PHD Assistant Professor, Neurobiology and Ophthalmology Stanford University School of Medicine Dr. Huberman received his PhD in Neuroscience from UC Davis. From 2005-2010 he was a Helen Hay Whitney Postdoctoral Fellow at Stanford University. From 2011 to 2015, he was an Assistant Professor in the Departments of Neuroscience, Biology and Ophthalmology at UC San Diego. In 2016, joined the faculty at Stanford University. Dr. Huberman is a Midknight Foundation Neuroscience Scholar, a Biomedical Scholar of the Pew Charitable Trust and in 2017, he received the ARVO Cogan Award for Contributions to Vision Science and Ophthalmology. Dr. Huberman is member of the Glaucoma Research Foundation Catalyst for a Cure Biomarker Initiative.

MARK S. HUMAYUN, MD, PHD Cornelius J. Pings Chair in Biomedical Sciences, Professor of Ophthalmology, Biomedical Engineering, and Integrative Anatomical Sciences, Director USC Institute for Biomedical Therapeutics Co-Director USC Rosski Eye Institute Dr. Humayun has dedicated 30 years to the development of the first FDA-approved bioelectronic artificial retina to restore sight to the blind and enable them to see large objects and letters. He has more than 200 peer-reviewed publications and 114 issued patents and is the recipient of the 2015 National Medal of Technology and Innovation — the nation’s highest award for technological achievement.

HENRY HSU, MD Chief Executive Officer Altrya Pharmaceuticals Dr. Hsu has extensive experience in all phases of drug development in multiple indications, including glaucoma, dry eye, and retinal diseases. Prior to founding Altrya, Henry was CEO of Allasco. He has led clinical development teams at Molecular Partners, CoMentis, and Plexiskan. Altrya is partnered with D. Western Therapeutics Institute (Japan) to advance a novel multi-kinase inhibitor for glaucoma into clinical trials in early 2018 in the United States. Dr. Hsu obtained his MD from UCSF.

MALIK Y. KAHOOK, MD Sister Family Endowed Chair in Ophthalmology, Vice Chair of Clinical and Translational Research, Chief, Glaucoma Service and Director of Glaucoma Fellowship, Professor of Ophthalmology University of Colorado Anschutz Medical Campus Dr. Kahook is Professor of Ophthalmology and the Sister Family Endowed Chair in Ophthalmology at the University of Colorado School of Medicine. He is Vice Chair of Clinical and Translational Research and is Chief of the glaucoma service and Director of the glaucoma fellowship at the University of Colorado Eye Center. Dr. Kahook has also received numerous awards and filed for over 30 patents with 20 licensed by companies for development. Four of his devices are currently in human trials or available globally for clinical use.

ROBERT KISSLING, MD Vice President, Medical Affairs Bausch + Lomb Robert Kissling, MD has more than 15 years of experience in the eye care industry and pharmaceutical industry including Pharmacon, NovaLis, QIL, GALderma, and Bauss + Lomb. Kissling is MD and PhD in Electrical Engineering and an MBA.

RAY KRAUSS, MBA Chief Executive Officer Canima Vision Ray has 35 years executive experience in the medical device industry, including 10 years at Johnson & Johnson (Venture Capital/Ophthalmology). He joined Summit Technology as CCO, the first company to receive FDA clearance for PKR in 1995. He has been CEO of several startups, raised financing from Angel Investors and VC firms, and has led the sale of two companies to strategic partners. Ray holds BS and MS degrees in Electrical Engineering and an MBA.

MICHAEL H. GOLSTEIN, MD, MBA Chief Medical Officer Ocular Therapeutix Dr. Golstein joined Ocular Therapeutix in 2017. Prior to that, Dr. Golstein served as CMO of Applied Genetic Technologies Corp, a clinical-stage biotechnology company focused on the treatment of rare ophthalmic diseases. Before joining AGTC, Dr. Golstein served as CMO and VP of Clinical Research at Elevon Biopharmaceuticals. Dr. Golstein serves as Co-Director, Camaea and External Disease Service and Assistant Professor of Ophthalmology at the New England Eye Center and Tufts University School of Medicine. Dr. Golstein holds an MD and an MBA from Northwestern University.

MARK S. HUMAYUN, MD, PHD Cornelius J. Pings Chair in Biomedical Sciences, Professor of Ophthalmology, Biomedical Engineering, and Integrative Anatomical Sciences, Director USC Institute for Biomedical Therapeutics Co-Director USC Rosski Eye Institute Dr. Humayun has dedicated 30 years to the development of the first FDA-approved bioelectronic artificial retina to restore sight to the blind and enable them to see large objects and letters. He has more than 200 peer-reviewed publications and 114 issued patents and is the recipient of the 2015 National Medal of Technology and Innovation — the nation’s highest award for technological achievement.

MELISSA LIEW, MD, FACS Assistant Professor, Neurology and Ophthalmology Stanford University School of Medicine Melissa Liew, MD, FACS is an Assistant Professor in the Departments of Neurology, Anatomy and Ophthalmology at Stanford University. She is a board-certified neurologist and glaucoma specialist with a special interest in the neurobiology of glaucoma. She has been instrumental in the development of novel therapeutic strategies for glaucoma, including retinal prostheses and other neuroplasticity-based approaches. Dr. Liew received her MD from the University of British Columbia and completed her neurology residency at the University of California, San Francisco. She is currently the Glaucoma Service Head at the University of California, San Francisco.

RICHARD A. LEWIS, MD Professor, Clinical Ophthalmology, Director, Glaucoma Service UCSC and the Zuckerberg San Francisco (ZSFG) General Hospital Dr. Lewis has a special interest in the neurobiology of glaucoma. His research focuses on the mechanisms of glaucomatous retinal ganglion cell death and the development of novel therapeutic strategies. He is a member of the American Glaucoma Society and The Glaucoma Foundation’s Clinician-Scientist Awards, and the Mid-Career Award by the AGS. As a Principal Investigator, his NIH’s study was funded by the NIH, in addition to his receiving many industry-funded trials including the Memantine Glaucoma Trial by Allergan and the Ranibizumab-Adjuvant Study for Ahmed Valve Surgery by Genentech. He has received the AAO’s Achievement Award, Senior Award, and Senior Achievement Award.

CYNTHIA MATTOX, MD, FACS Assistant Professor and Vice Chair, Department of Ophthalmology at Tufts University School of Medicine; Director of the Glaucoma and Cataract Service at the New England Eye Center Dr. Mattox has served on the American Glaucoma Society’s (AGS) Board since 2008 and was elected President in 2017. She has served on the Health Policy committee of the American Academy of Ophthalmology (AAO) for many years. In 2014, she received the Outstanding Advocate Award from the AGA, and in 2016 was elected to a four-year term on the AAO Board of Directors. Along with her busy practice, Dr. Mattos trains glaucoma fellows and residents in glaucoma and cataract management and surgery, and has received the Resident Teaching Award three times.
A restorative approach to IOP control.

SLT and ABiC™ work to control IOP by a process of restoration of the natural outflow pathways. This is in contrast to traditional glaucoma surgeries and other MIGS procedures, which attempt to mechanically change or bypass the pathway of aqueous outflow.

SLT stimulates a process of cellular regeneration to create a healthier, more porous TM structure. On average, SLT achieves a 30% reduction in IOP when used as a first-line therapy.

ABiC™ is a new ab-interno MIGS procedure that flushes out the natural outflow channels, without damaging tissue, to achieve an average IOP reduction of 30%*.

**PREVIEW THE BREAKTHROUGH Tango Reflex™ SLT/AFR/YAG LASER AT GLAUCOMA 360**

**LEARN MORE AT WWW.ELLEX.COM/SLT-ABIC-NATURAL-PARTNERSHIP**
HEATHER PRESTON, MD  
Partner and Managing Director  
TPG Biotech  
Prior to TPG Biotech, Dr. Preston focused on medical device and biotechnology venture capital investing at JP Morgan Partners. Previously, she was an Entrepreneur-in-Residence with New Enterprise Associates. She worked at McKinsey & Co. where she was a leader of their pharmaceutical and medical products consulting practice. Dr. Preston currently serves on the board of directors of Albireo, Inc., Alder BioPharmaceuticals, Otonomy, Inc., Unchained Labs, Avanir Pharmaceuticals, Aura Ophthalmics and Entreos, Inc. She earned her MD from the University of Oxford and completed a molecular biology post-doctoral fellowship at Dana Farber Cancer Institute, Harvard University. She trained in Internal Medicine at Massachusetts General Hospital and subspecialized in Gastroenterology and Hepatology at UCSF.

CHRIS PULLING  
Chief Executive Officer  
MicroOptx  
Prior to MicroOptx, Chris was CEO of The Integra Group, a contract research organization he founded in 2002. He led Integra from formation through acquisition by the world’s largest medical device CRO. At Integra, Chris and his staff supported over 400 medical device companies, and he was integrally involved in over 30 PMA approvals and 10 FDA advisory panels. Previous management experience also includes Medtronic. Chris has an MS in Biostatistics from the University of Minnesota and a BA in Mathematics from Hamline University.

JANE RADY  
Vice President, Business Development  
Johnson & Johnson Vision  
Prior to joining Johnson & Johnson Vision and Abbott Medical Optics, Ms. Rady was a director and the CEO of Integrated Genomics, Inc., held senior positions within G.D. Searle & Co., and headed venture investing in Monsanto focusing on emerging technologies and businesses in biotechnology. Ms. Rady began her career with Abbott Laboratories. She received her Bachelor and Master of Science from the University of Illinois in molecular biology/microbiology and her MBA from Northwestern’s Kellogg School of Management.

ANGELO RAGO  
Head of Ophthalmic Diagnostics  
Carl Zeiss Meditec, Inc.  
Currently Mr. Rago is focused on Retina and Glaucoma and the Routine Diagnostics businesses. He joined ZEISS as Head of Business Sectors and Innovation within the Strategic Business Unit Ophthalmic Systems. Previously, Mr. Rago held various management positions in Equipment Operations and Global Customer Care for Abbott Medical Optics (AMO). Prior to AMO, he spent 17 years with Siemens Medical Solutions, where he held senior positions in both Service and Product Development areas. He holds a BS in Mechanical Engineering and an Executive Certification in Innovation & Strategy from MIT’s Sloan School of Business.

MICHAEL R. ROBINSON, MD  
Vice-President, Therapeutic Area Head, Anterior Segment and Consumer Eye Care  
Allergan, Inc.  
Dr. Robinson is a board-certified ophthalmologist who completed 3 years of post-doctoral fellowship training at the National Eye Institute with a focus on ocular drug delivery. Given his broad clinical and research background, Dr. Robinson has served in multiple leadership roles at Allergan including Global Project Team Lead and Clinical Lead on projects related to ocular drug delivery in dry eye, retina and glaucoma therapeutic areas. He has over 20 issued patents that include Bimatoprost SR and Brimonidine DDS, both in late stages of clinical development.

CHERYL ROWE-RENDLEMAN, PHD  
Managing Consultant  
Omar Consulting Group, LLC  
Dr. Rowe-Rendleman is a clinical research and development professional at Omar Consulting Group, an ophthalmology consulting practice specializing in creating business, regulatory, and clinical development know-how for people and companies interested in eye diseases. A graduate of Princeton University with graduate fellowships in developmental and degenerative ophthalmic diseases from the University of Texas and UCSF Medical Schools, Cheryl has participated in over 100 US and Ex-US clinical development programs in areas of macular degeneration, diabetic retinopathy, ocular inflammation, anti-infectives, refractive disorders, glaucoma, and ocular surface disease.
SPEAKERS, MODERATORS, PARTICIPANTS

JOEL S. SCHUMAN, MD, FACS
Professor and Chairman of Ophthalmology
NYU Langone Medical Center, New York University School of Medicine
Professor of Electrical and Computer Engineering
NYU Tandon School of Engineering
Dr. Schuman was appointed Chair of the Department of Ophthalmology for the NYU Langone Medical Center in 2016. Dr. Schuman and his colleagues invented optical coherence tomography (OCT), now standard of care for clinical use worldwide for the diagnosis and management of eye disease. His team was also the first to identify a molecular marker for human glaucoma, published in Nature Medicine in 2001. Dr. Schuman is a productive researcher, and has been continuously funded by the National Eye Institute since 1995. He serves on the Glaucoma Research Foundation’s Catalyst for a Cure Biomarker Initiative’s Advisory Board.

CHRISTIE SHAFFER, PHD
Partner
Hatteras Ventures
Christy Shaffer, PhD has over 25 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals. Dr. Shaffer serves as a board member of five Hatteras portfolio companies and chairs three of them: Clearside (Chair), KinoDyn (Chair), and GrayBug (Executive Chair). She is a receptor pharmacologist by training, earning her PhD in Pharmacology from the University of Tennessee Health Science Center. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

KULDEV SINGH, MD, MPH
Professor of Ophthalmology
Director of Glaucoma Service
Stanford University School of Medicine
Singh has served as President of the American Glaucoma Society and Executive Vice President of the World Glaucoma Association. He is presently a Standing Member on the Medical Devices Advisory Committee of the US Food and Drug Administration. Dr. Singh received his MD and MPH degrees from the Johns Hopkins University School of Medicine and was an Eleanor Naylor Dana Charitable Trust Fellow at the Wilmer Eye Institute. He completed his ophthalmology residency at Casey Eye Institute and his glaucoma fellowship at the Bascom Palmer Eye Institute.

CLARK E. TEDFORD, PHD
Co-Founder, President and Chief Executive Officer
LumiThera
Dr. Tedford is one of the founders of LumiThera and has served as President and CEO since the formation of the company. Previously he was VP and Chief Science Officer at PhotoThera. Prior to that Dr. Tedford was the VP, Pharmaceutical Research at Omeros, and previously at Omeros, Dr. Tedford was President of Solentix, Inc. During Dr. Tedford’s 25 years in the pharmaceutical and medical device industry, he has held several scientific and executive management positions. Dr. Tedford received his PhD in pharmacology from the University of Iowa and completed post-doctoral work at the Loyola University Medical School.

KAREN Y. TORREJON, PHD
Founder, Chief Science Officer
Glauconix Therapeutics
During graduate research supported by the National Science Foundation Graduate Research Fellowship Program (NSF GRFP), Dr. Torrejon invented 3D human eye tissue, known as the 3D Human Trabecular Meshwork (3D-HTM). She developed this proprietary technology which is currently being utilized for Glauconix services. Dr. Torrejon has been recognized by the MIT Technology Review and one of the “35 under 35” innovations of the year (2015). She received her BS in both Chemistry and Physics from the State University of New York (SUNY) at Albany and her PhD in Nanoscale Engineering from SUNY Polytechnic Institute.

BRETT A. TRAUTHEN
Chief Scientific Officer
Ivantis, Inc.
Mr. Trauthen is the Chief Scientific Officer for Ivantis, Inc, developer of the Hydrus Microstent, a novel surgical device for IOP reduction in glaucoma. Prior to Ivantis, he was the Chief Scientific Officer at Dexta Inc and Conor Medsystems, developers of drug eluting coronary stents. Mr. Trauthen has directed over 20 clinical studies on novel technologies in ophthalmic and cardiovascular disease. He has a BS in Engineering from UC Berkeley and an MS is Engineering from UC Irvine.
JAMES C. TSAI, MD, MBA  
President of New York Eye and Ear Infirmary of Mount Sinai  
Chair of Ophthalmology, Mount Sinai Health System  
Doheny-Rodgers Professor of Ophthalmology,  
Icahn School of Medicine at Mount Sinai  
Dr. Tsai serves as Chair of the Glaucoma Subcommittee of the National Eye Health Education Program Planning Committee of the National Institutes of Health (NIH), Associate Examiner for the American Board of Ophthalmology, and Treasurer of the International Joint Commission on Allied Health Personnel in Ophthalmology. Dr. Tsai earned his MD from Stanford University School of Medicine and his MBA from the Kellogg School of Management at Northwestern University, and a PharmD from the University of Florida. In addition to his career in medicine, Dr. Tsai is the founder of ophthalmic device company Ocunetics, Inc. whose intellectual property was exclusively licensed by IRIDEX Corporation in 2011.

JEFF WELLS, PHARM.D  
Senior Vice President of Clinical, Regulatory, and Quality  
Glaukos Corporation  
Prior to working at Glaukos, Jeff was Senior VP of Product Development at Bioform, and held various roles at Santen Inc, including VP US R&D, VP Clinical and Regulatory Affairs for the US and Europe, and Director of Marketing. Prior to Santen, he worked at Bausch + Lomb, where he launched Lotemax and several other products. Jeff holds a BS and BA from Ohio Northern University, a Masters in Management (MBA) from the Kellogg School at Northwestern University, and a PharmD from the University of Florida.

MOLLY WALSH, MD  
Co-founder and Chief Executive Officer  
Retroject, Inc.  
Dr. Walsh is the co-founder and CEO of Retroject, Inc., a company that she started with her late colleague, Dr. David Epstein. Dr. Walsh is a glaucoma specialist at Duke University Eye Center where numerous patients are treated daily for unnecessary vision loss due to the inadequacies of topical therapies. Her research interests are focused on a device that enables delivery of therapeutic agents directly to the sites responsible for causing elevated intraocular pressure in glaucoma, the trabecular meshwork and Schlemm’s canal.

TRACY M. VALORIE, MBA  
Senior Vice President and General Manager US Pharmaceutical and Surgical  
Bausch + Lomb  
Ms. Valorie is the Senior Vice President and General Manager of Bausch + Lomb Pharmaceuticals and Valiant Women’s Health and previously served as the Global Head of Glaucoma. Prior to that, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products, mid-stage development portfolio, and long-range planning. Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing, and strategic planning. Ms. Valorie has held board membership seats at The Glaucoma Foundation, ARVO Foundation for Eye Research, and OWL.

STEVEN D. VOLD, MD  
Founder and Chief Executive Officer  
Vold Vision  
Chief Medical Editor  
Glaucoma Today  
Dr. Vold founded Vold Vision after previously serving as Vice Chairman of the Department of Ophthalmology and Director, Division of Glaucoma at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas. He has been listed in the Consumer’s Research Council of America’s Guide to America’s Top Ophthalmologists every year since 2002. He currently serves as Chief Medical Editor of Glaucoma Today, and co-founded the American-European Congress of Ophthalmic Surgery. Dr. Vold also co-founded the ophthalmic device company OcuTecns, Inc. whose intellectual property was exclusively licensed by IRIDEX Corporation in 2011.

JEFF WELLS, PHARM.D  
Senior Vice President of Clinical, Regulatory, and Quality  
Glaukos Corporation  
Prior to working at Glaukos, Jeff was Senior VP of Product Development at Bioform, and held various roles at Santen Inc, including VP US R&D, VP Clinical and Regulatory Affairs for the US and Europe, and Director of Marketing. Prior to Santen, he worked at Bausch + Lomb, where he launched Lotemax and several other products. Jeff holds a BS and BA from Ohio Northern University, a Masters in Management (MBA) from the Kellogg School at Northwestern University, and a PharmD from the University of Florida.

MOLLY WALSH, MD  
Co-founder and Chief Executive Officer  
Retroject, Inc.  
Dr. Walsh is the co-founder and CEO of Retroject, Inc., a company that she started with her late colleague, Dr. David Epstein. Dr. Walsh is a glaucoma specialist at Duke University Eye Center where numerous patients are treated daily for unnecessary vision loss due to the inadequacies of topical therapies. Her research interests are focused on a device that enables delivery of therapeutic agents directly to the sites responsible for causing elevated intraocular pressure in glaucoma, the trabecular meshwork and Schlemm’s canal.

TRACY M. VALORIE, MBA  
Senior Vice President and General Manager US Pharmaceutical and Surgical  
Bausch + Lomb  
Ms. Valorie is the Senior Vice President and General Manager of Bausch + Lomb Pharmaceuticals and Valiant Women’s Health and previously served as the Global Head of Glaucoma. Prior to that, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products, mid-stage development portfolio, and long-range planning. Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing, and strategic planning. Ms. Valorie has held board membership seats at The Glaucoma Foundation, ARVO Foundation for Eye Research, and OWL.

JEFF WELLS, PHARM.D  
Senior Vice President of Clinical, Regulatory, and Quality  
Glaukos Corporation  
Prior to working at Glaukos, Jeff was Senior VP of Product Development at Bioform, and held various roles at Santen Inc, including VP US R&D, VP Clinical and Regulatory Affairs for the US and Europe, and Director of Marketing. Prior to Santen, he worked at Bausch + Lomb, where he launched Lotemax and several other products. Jeff holds a BS and BA from Ohio Northern University, a Masters in Management (MBA) from the Kellogg School at Northwestern University, and a PharmD from the University of Florida.

MOLLY WALSH, MD  
Co-founder and Chief Executive Officer  
Retroject, Inc.  
Dr. Walsh is the co-founder and CEO of Retroject, Inc., a company that she started with her late colleague, Dr. David Epstein. Dr. Walsh is a glaucoma specialist at Duke University Eye Center where numerous patients are treated daily for unnecessary vision loss due to the inadequacies of topical therapies. Her research interests are focused on a device that enables delivery of therapeutic agents directly to the sites responsible for causing elevated intraocular pressure in glaucoma, the trabecular meshwork and Schlemm’s canal.

TRACY M. VALORIE, MBA  
Senior Vice President and General Manager US Pharmaceutical and Surgical  
Bausch + Lomb  
Ms. Valorie is the Senior Vice President and General Manager of Bausch + Lomb Pharmaceuticals and Valiant Women’s Health and previously served as the Global Head of Glaucoma. Prior to that, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products, mid-stage development portfolio, and long-range planning. Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing, and strategic planning. Ms. Valorie has held board membership seats at The Glaucoma Foundation, ARVO Foundation for Eye Research, and OWL.
Founded in 1978 in San Francisco, Glaucoma Research Foundation was created to encourage innovative research to find better ways to care for people with glaucoma and ultimately find a cure.

Over the past 40 years, Glaucoma Research Foundation has funded pioneering and transformational studies to advance the field of glaucoma. An important funding priority is fostering collaborative research in order to speed the pace of discovery. Landmark projects include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision, and the establishment of the Catalyst for a Cure (CFC) research consortium.

Established in 2001, our first CFC team focused on neuroprotection and fundamentally changed how the scientific and medical communities view vision loss in glaucoma. Based on this successful model, the second CFC team was recruited and charged with identifying new biomarkers to indicate the earliest signs of glaucoma. The researchers have moved their investigations from the laboratory into the clinic for human studies of the most promising biomarkers they have identified. The impact of this research will be valuable for both patients and doctors as it has the potential to transform how glaucoma is diagnosed and managed in the future.

COMMITMENT TO EDUCATION AND AWARENESS
Glaucoma Research Foundation remains a principal source of information and support for doctors, patients and their families. We distribute more than 120,000 issues of our Gleams newsletter three times a year through the mail, by doctors’ offices and by email. Our website, www.glaucoma.org, helps more than 4 million visitors annually with useful and accurate information. Both our website and our educational booklet “Understanding and Living with Glaucoma” continue to be primary resources for patients seeking to learn more about their glaucoma diagnosis, treatment options, and Glaucoma Research Foundation’s research initiatives.

THE CURE IS IN SIGHT CAMPAIGN
In April 2017, The Cure is in Sight — The Campaign for Glaucoma Research Foundation was launched with the goal to raise $15 million by June 2018. This historic fundraising endeavor will reinforce our mission, strengthen our education and support efforts, and make possible great strides in scientific discovery. In 2018, we will close the Campaign and mark the 40th anniversary of the founding of Glaucoma Research Foundation. As we celebrate these important milestones, we incredibly grateful for the outstanding support and dedication of our donors and volunteers. Because of you, the cure is truly in sight.